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Background: Thiamine is a vitamin that is essential for adequate aerobic metabolism. The objective of this study
was to determine if thiamine administration prior to coronary artery bypass grafting would decrease post-operative
lactate levels as a measure of increased aerobic metabolism.
Methods: We performed a randomized, double-blind, placebo-controlled trial of patients undergoing coronary
artery bypass grafting. Patients were randomized to receive either intravenous thiamine (200 mg) or placebo both
immediately before and again after the surgery. Our primary endpoint was post-operative lactate levels. Additional
endpoints included pyruvate dehydrogenase activity, global and cellular oxygen consumption, post-operative
complications, and hospital and intensive care unit length of stay.
Results: Sixty-four patients were included. Thiamine levels were significantly higher in the thiamine group as
compared to the placebo group immediately after surgery (1200 [683, 1200] nmol/L vs. 9 [8, 13] nmol/L, p < 0.001).
There was no difference between the groups in the primary endpoint of lactate levels immediately after the
surgery (2.0 [1.5, 2.6] mmol/L vs. 2.0 [1.7, 2.4], p = 0.75). Relative pyruvate dehydrogenase activity was lower
immediately after the surgery in the thiamine group as compared to the placebo group (15 % [11, 37] vs. 28 %
[15, 84], p = 0.02). Patients receiving thiamine had higher post-operative global oxygen consumption 1 hour after
the surgery (difference: 0.37 mL/min/kg [95 % CI: 0.03, 0.71], p = 0.03) as well as cellular oxygen consumption. We
found no differences in clinical outcomes.
Conclusions: There were no differences in post-operative lactate levels or clinical outcomes between patients
receiving thiamine or placebo. Post-operative oxygen consumption was significantly increased among patients
receiving thiamine.
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Over 230,000 patients in the United States undergo
coronary artery bypass grafting (CABG) each year [1].
Although mortality in this patient population is relatively
low, complications increasing both morbidity and length
of stay remain significant [2–4]. Lactate elevation, a
marker of anaerobic metabolism, is commonly seen after
major cardiac surgery and multiple studies have found an
association between elevated post-operative lactate levels
and increased morbidity and mortality [5–10]. Elevated
lactate has also been associated with poor outcome in
other forms of critical illness, such as sepsis [11, 12]. The
rise in lactate in these settings is thought to be secondary
to inadequate oxygen delivery and/or a deficit in aerobic
metabolism [13]. The importance of this decrease in
aerobic metabolism is also supported by an association
between low oxygen consumption and poor outcome in
critically ill states including sepsis, high-risk surgery, and
post-cardiac arrest patients [14–16].
Aerobic metabolism occurs when pyruvate enters the
mitochondria through pyruvate decarboxylation to acetyl-
coenzyme A. This entry into the mitochondria (and tri-
carboxylic acid [TCA] cycle) is facilitated by the rate-
limiting enzyme pyruvate dehydrogenase (PDH) (Fig. 1)
[17, 18]. Decreased PDH activity may cause a shift towardFig. 1 Simplified graphical presentation of PDH’s and thiamine’s role
in aerobic metabolism. Aerobic metabolism occurs when pyruvate
enters the mitochondria through pyruvate decarboxylation to
acetyl-coenzyme A, facilitated by the rate-limiting enzyme pyruvate
dehydrogenase (PDH). Adapted with permission from Andersen et al.
[12]. ATP adenosine triphosphate, CoA coenzyme A, TCA tricarboxylic acidanaerobic metabolism and potentially play a role in the
metabolic changes (i.e., elevated lactate) seen in pa-
tients undergoing CABG with cardiopulmonary bypass
[19–24]. Thiamine (vitamin B1) is an essential co-factor
for PDH function. In the absence of thiamine, the con-
version of pyruvate to acetyl-coenzyme A is inhibited, cel-
lular oxygen consumption is decreased, and lactate is
produced [25]. Thiamine deficiency is common after car-
diac surgery and post-operative thiamine levels have been
found to be inversely associated with post-operative lac-
tate levels [19, 26].
We hypothesized that thiamine administration prior to
surgery would decrease post-operative lactate levels in
patients undergoing CABG by increasing PDH activity




This was a single-center, randomized, double-blind,
placebo-controlled, phase II trial of thiamine in patients
undergoing CABG with cardiopulmonary bypass. Patients
were enrolled at Beth Israel Deaconess Medical Center,
Boston, MA, USA - a tertiary care center with more than
450 CABG surgeries performed annually. The study was
approved by The Committee on Clinical Investigations at
Beth Israel Deaconess Medical Center (protocol number:
2014-P000257) and patients provided written informed
consent prior to enrollment. The trial was registered
at clinicaltrials.gov (NCT02322892) and funded by the
American Heart Association (15CRP22830000).
Study population
We enrolled consecutive patients between January 2015
and July 2015. We included adult patients (≥21 years)
scheduled for CABG with or without concomitant valve
procedures. Due to unpublished preliminary data sug-
gesting that patients with a higher European System for
Cardiac Operative Risk Evaluation (EuroSCORE) II score
have higher post-operative lactate levels, we only included
patients with a EuroSCORE II score > 1.5 %. We excluded
patients based on the following criteria: (1) current
thiamine supplementation or known clinical indication for
thiamine (e.g., alcohol dependency), (2) known allergy to
thiamine, (3) emergent or salvage CABG (as defined by
the Society of Thoracic Surgeons [27]), (4) CABG without
cardiopulmonary bypass (“off-pump” surgery), and (5)
protected population (pregnant women, prisoners, and
the intellectually disabled).
Randomization, study drug and blinding
Patients were randomized in blocks of four in a 1:1 ratio
to receive thiamine or placebo. The randomization was
stratified by “high” (>4 %) vs. “low” (≤4 %) EuroSCORE
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groups. Patients received 200 mg thiamine in 50 mL 0.9 %
saline or matching placebo (50 mL 0.9 % saline) immedi-
ately before the surgery and again immediately after the
surgery upon arrival in the intensive care unit. The
placebo and the thiamine were identical in appearance;
patients, healthcare personnel, and the research team
remained blinded throughout the study period.
Endpoints and data collection
The primary endpoint was post-operative lactate levels
collected upon arrival to the intensive care unit. Key sec-
ondary endpoints included PDH activity, post-operative
complications, intensive care unit and hospital length of
stay, and mortality. Additional endpoints included lac-
tate levels 6 hours after the surgery, time on mechanical
ventilation (defined as the time from the end of surgery
until extubation), time on vasopressors (defined as the
time from the end of surgery until discontinuation of all
vasopressors [epinephrine, norepinephrine, phenyleph-
rine, dopamine, and vasopressin] for at least 6 hours),
and cellular and global oxygen consumption (see below).
Post-operative complications before hospital discharge
included: new atrial fibrillation (requiring treatment or
lasting for > 24 hours), renal failure (requiring new dialysis),
stroke as defined by Sacco et al. [28], myocardial infarction
using the universal definition [29], acute respiratory dis-
tress syndrome using the Berlin definition [30], infection
(requiring new antibiotics), and documented delirium.
Before the surgery, we recorded demographic data and
past medical history including the New York Heart Associ-
ation (NYHA) classification [31] and the Canadian Cardio-
vascular Society grading of angina pectoris [32]. We also
calculated the EuroSCORE II [33], which is a validated
pre-operative score to predict post-operative morbidity and
mortality [34–36]. The score utilizes information regarding
the patient (age, gender, and co-morbidities) and current
cardiac status (NYHA class, presence of unstable angina,
left ventricular function and more), as well as factors re-
lated to the operation (urgency and type of intervention).
All data were collected by a trained research assistant
according to a detailed, pre-defined data dictionary and
all outcome variables were verified by a physician. Data
were entered into a secure, online database (Research
Electronic Data Capture [RedCAP]) [37].
Blood samples
Blood samples were obtained immediately before adminis-
tration of the first study dose, upon arrival to the intensive
care unit (immediately before administration of the sec-
ond study dose), and again 6 hours later. Upon collection,
blood was sent to the hospital’s clinical laboratory for
lactate measurements (Rapidlab 1265, Siemens Healthcare
Diagnostics Inc., Tarrytown, NY, USA). Fresh whole bloodcollected in ethylenediaminetetraacetic acid tubes was
used for measurement of PDH and cellular oxygen con-
sumption (see below). The remaining blood was centri-
fuged at 3500 rpm for 10 minutes. Plasma and serum
were aliquoted into light-protected cryotubes and frozen
at −80 °C for later measurements of thiamine levels. All
blood samples were collected from pre-existing arterial
lines except one draw that was collected from a pre-
existing central venous line.Thiamine levels and pyruvate dehydrogenase
Thiamine levels were measured in plasma via liquid
chromatography-tandem mass spectrometry by Quest
Diagnostics (Nichols Institute, Chantilly, VA, USA).
Absolute thiamine deficiency was determined using a pre-
viously established standard laboratory reference range
from Quest Diagnostics; specifically, absolute thiamine
deficiency was defined as a level ≤ 7 nmol/L. If a thiamine
level was undetectable (i.e., < 7 nmol/L) a value of 7 nmol/
L was imputed.
Peripheral blood mononuclear cells (PBMCs) were
isolated from fresh whole blood using a density gradient
separation method (Ficoll-Paque premium, GE Healthcare
Bio-Science Corp., Piscataway, NJ, USA). PDH activity
and quantity were then measured after disruption of the
mitochondrial membrane via an immunocapture and
microplate-based assay as previously described [38, 39].
PDH specific activity was calculated as PDH activity/ln
(PDH quantity). PDH activity and quantity are expressed
in OD/min/mg protein where OD indicates the absorb-
ance (optical density). Post-operative PDH values are
expressed as relative to the pre-operative PDH value (i.e.,
[PDHpost-surgery/PDHpre-surgery] × 100 %).Global and cellular oxygen consumption
Based on equipment availability, we measured global
oxygen consumption (VO2) in a subset of patients using
a compact anesthesia monitor, which was connected to
the ventilator tubing via a ventilator adapter with an at-
tached gas sampling line (General Electric, Fairfield, CT,
USA). This device measures VO2 continuously on a
breath-by-breath basis using an incorporated pneumo-
tachograph to measure the volume of gas being exchanged,
and a paramagnetic analyzer to detect differences in
inspired and expired oxygen [40, 41]. The monitor
does not measure VO2 when the fraction of inspired
oxygen is > 85 %. VO2 was recorded every 5 minutes
from arrival in the intensive care unit until extubation
or until the second post-operative blood draw. For the
analysis, we used data from 1 hour after the surgery until
4 hours after the surgery. We removed non-physiological
outliers (VO2 < 150 mL/min and VO2 > 700 mL/min) and
very inconsistent values (i.e., single values that changed
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ized to body weight.
Based on laboratory personnel and equipment avail-
ability (as the measurement must be performed at the
time of sample collection), we measured the cellular
oxygen consumption rate (OCR) in PBMCs on a subset
of the enrolled patients. The complete mitochondrial
respiration profile was measured using the XF Cell Mito
Stress Test Kit in an XFe96 Extracellular Flux Analyzer
(Seahorse Bioscience, North Billerica, MA, USA). This
technology has been described in detail elsewhere [42].
For this manuscript, we report basal cellular respiration as
well as maximal cellular respiration (see Additional file 1).
The value of interest was the immediate post-surgery
OCR relative to the pre-surgery OCR (i.e., [OCRpost-surgery/
OCRpre-surgery] × 100 %).
Sample size calculation and statistical analysis
The sample size for the current study was based on un-
published preliminary data from a small open-label trial
of thiamine administration and historical observational
data (see Additional file 1). Based on this, we estimated
that the placebo group would have a mean post-operative
lactate level of 3.6 mmol/L and that the thiamine group
would have a mean lactate level of 2.6 mmol/L with both
groups having a standard deviation of 1.4 mmol/L. Based
on these estimates, 32 patients in each group provide
80 % power for a two-sided t test at an alpha level of 0.05.
Descriptive statistics were used to characterize the study
population; continuous variables are presented as means
with standard deviations or medians with 1st and 3rd quar-
tiles depending on the normality of the data. Categorical
variables are presented as counts with relative frequencies.
Continuous data were compared between the groups
using a two-sample t test or Wilcoxon rank sum test de-
pending on normality of the data. Categorical data were
compared between groups using Fisher’s exact test. The
primary analysis was a comparison of lactate levels imme-
diately after the surgery. Secondarily, we used repeated
measures analysis to analyze lactate levels immediately
and 6 hours after surgery using an unstructured variance-
covariance structure adjusting for the pre-surgery level as
well as the stratification factor (i.e., low vs. high Euro-
SCORE II) [43]. PDH levels and VO2 were similarly ana-
lyzed using a repeated measures approach. For the latter
analysis, we assumed a 1st order autoregressive variance-
covariance structure. OCR was compared between groups
using linear regression with adjustment for the stratifica-
tion factor. Right-skewed variables (lactate, PDH values
and OCR) were log-transformed before analysis.
We performed three subgroup analyses for the primary
endpoint; according to the stratification variable, according
to the pre-surgery thiamine level (dichotomized as above/
below the median) and according to whether the patienthad diabetes or not as a relatively large proportion of pa-
tients with diabetes may have thiamine deficiency [44, 45].
Analyses were conducted on a modified intention-to-
treat basis including only those subjects who received
the first dose of the study drug [46]. Data were complete
for the primary endpoint and no imputations were done
for missing secondary outcomes. All statistical analyses
were pre-defined (i.e., planned before unblinding of the
data) unless otherwise specified. All hypothesis tests were
two-sided, with a significance level of p < 0.05. Given the
pilot nature of the current study, no adjustments were
made for multiple testing and all secondary outcomes
should therefore be considered exploratory. Statistical
analyses were conducted with the use of SAS software,
version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Study population and thiamine levels
Of 275 patients screened, 69 were randomized and 64 re-
ceived the first study dose and were therefore included in
the analysis (Fig. 2). One patient was scheduled for CABG
and valve surgery but only received valve surgery. Per our
pre-defined analysis plan, this patient was not excluded.
The baseline characteristics of the patients are pro-
vided in Table 1 and surgical characteristics in Table 2.
There were no statistically significant differences in
surgical characteristics between the groups. There was no
difference in the pre-operative lactate levels between the
groups (1.2 mmol/L [1.0, 1.3] vs. 1.1 mmol/L [1.0, 1.3]).
Thiamine levels were similar between the thiamine and
placebo group prior to the surgery (14 nmol/L [11, 18] vs.
14 nmol/L [12, 18]) with one patient in the thiamine
group and zero patients in the placebo group having
thiamine deficiency. Thiamine levels were substantially
higher in the thiamine group as compared to the placebo
group immediately after surgery (1200 nmol/L [683, 1200]
vs. 9 nmol/L [8, 13], p < 0.001) and 6 hours after the
surgery (1200 nmol/L [872, 1200] vs. 10 nmol/L [7, 15],
p < 0.001). No patients in the thiamine group were defi-
cient after the surgery as compared to three (9 %) in the
placebo group immediately after the surgery (p = 0.24) and
five (15 %) patients 6 hours after the surgery (p = 0.05).
Lactate and PDH values
There was no difference between the thiamine and placebo
groups in the primary endpoint of lactate levels immedi-
ately after the surgery (2.0 mmol/L [1.5, 2.6] vs. 2.0 mmol/L
[1.7, 2.4], p = 0.75, Fig. 3). There was no difference in lactate
levels 6 hours after the surgery (1.8 mmol/L [1.3, 2.1] vs.
1.8 mmol/L [1.4, 2.6], p = 0.45, Fig. 3). There was no differ-
ence in post-operative lactate levels when analyzed in the
repeated measures model (p = 0.76).
The PDH values are presented in Fig. 4. Relative PDH
activity was significantly lower immediately after the
Fig. 2 CONSORT diagram. Out of 275 patients screened, 69 were randomized and 64 were analyzed per the modified intention-to-treat analysis.
No patients discontinued the intervention or were lost to follow-up. CABG coronary artery bypass grafting, EuroSCORE European System for
Cardiac Operative Risk Evaluation
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cebo group (15 % [11, 37] vs. 28 % [15, 84], p = 0.02).
There was no difference 6 hours after the surgery (23 %
[9, 50] vs. 29 % [12, 78], p = 0.19). There was no differ-
ence in relative PDH quantity immediately after the sur-
gery (43 % [22, 75] vs. 50 % [15, 96], p = 0.93) or 6 hours
after the surgery (56 % [23, 75] vs. 74 % [24, 111], p =
0.27). Relative PDH specific activity was lower in the
thiamine group immediately after surgery (19 % [14, 42]
vs. 39 % [20, 87], p = 0.01), but there was no difference
6 hours after surgery (27 % [12, 59] vs. 41 % [14, 77], p =
0.23). Given some imbalance between groups in PDH ac-
tivity at baseline, we performed a post hoc analysis includ-
ing the baseline PDH activity in the model. In this model,
the difference between the two groups in relative PDH
activity immediately after the surgery was not significant
(p = 0.12). A post hoc comparison of absolute PDH values
are presented in Additional file 1. There was no group
difference between any of the absolute PDH values.Oxygen consumption
Global oxygen consumption (VO2) was measured on 27
patients: 15 in the placebo group and 12 in the thiamine
group. There was no significant difference in baseline
characteristics between those who had and those who
did not have VO2 measured (see Additional file 1). There
was a significant difference in VO2 1 hour after surgery
with the thiamine group having higher values (differ-
ence: 0.37 mL/min/kg [95 % CI: 0.03, 0.71], p = 0.03).
There was no difference between the groups in change
in VO2 over time from 1 to 4 hours after the surgery
(p = 0.36). When the non-significant interaction was
removed from the model, the between-group difference
remained (difference: 0.19 mL/min/kg [95 % CI: 0.05,
0.33], p = 0.01) indicating that patients in the thiamine
group had consistently higher VO2 values from one to
four hours after the surgery.
Basal cellular oxygen consumption was available on 40
patients (20 in the placebo group and 20 in the thiamine
Table 1 Baseline characteristics of the study patientsa
Thiamine (n = 31) Placebo (n = 33)
Demographics
Age (years) 71 (67, 75) 73 (68, 79)
Sex (female) 6 (19) 10 (30)
Body mass index (kg/m2) 29 (26, 33) 28 (25, 29)
Race
White 31 (100) 32 (97)
Black 0 (0) 1 (3)
EuroSCORE II (%) 3.4 (2.1, 5.2) 2.3 (1.9, 4.5)
EuroSCORE II > 4.0 % 9 (29) 12 (36)
Cardiac past medical history
MI/PCI 14 (45) 12 (36)
Atrial fibrillation 7 (23) 5 (15)
Previous cardiac surgery 0 (0) 2 (6)
Chronic heart failure 4 (13) 8 (24)
Valve disease 12 (39) 8 (24)
Ejection fraction (%) 53 (40, 60) 55 (45, 60)
Current NYHA classb
I 5 (16) 1 (3)
II 12 (29) 14 (42)
III 14 (45) 15 (45)
IV 0 (0) 3 (9)
Current angina classb
No symptoms 13 (42) 14 (42)
I 0 (0) 1 (3)
II 3 (10) 5 (15)
III 7 (23) 7 (21)
IV 8 (26) 8 (18)
Other past medical history
Pulmonary disease 3 (10) 5 (15)
Diabetes 14 (45) 14 (42)
Insulin dependent 7 (50) 6 (43)
Non-insulin dependent 7 (50) 8 (57)
Renal disease 7 (23) 11 (33)
Cancer 1 (3) 2 (6)
Pre-operative laboratory values
White blood count (×103) 8.2 (6.8, 8.9) 7.5 (5.7, 10.0)
Hemoglobin (g/dL) 12.9 (11.5, 14.4) 13.0 (11.2, 14.2)
Creatinine (mg/dL) 1.1 (0.8, 1.6) 1.1 (0.8, 1.3)
Glucose (mg/dL) 131 (108, 164) 114 (94, 145)
Pre-surgical characteristics
Status
Elective 14 (45) 12 (36)
Urgent 17 (55) 21 (65)
Table 1 Baseline characteristics of the study patientsa
(Continued)
Location prior to surgery
Home 13 (42) 9 (27)
Ward 15 (48) 24 (73)
Intensive care unit 3 (10) 0 (0)
Abbreviations: EuroSCORE European System for Cardiac Operative Risk
Evaluation, MI myocardial infarction, PCI percutaneous coronary intervention,
NYHA New York Heart Association
aCategorical variables are presented as count (frequency) and continuous
variables as median (quartiles)
bDefined as the worst classification within the last 2 weeks
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characteristics between those who had and those who did
not have cellular oxygen consumption measured except
for a slightly higher EuroSCORE II in those without cellu-
lar oxygen consumption measured (see Additional file 1).
We found a significant difference in post-operative relative
basal oxygen consumption between the thiamine and
placebo group (99 % [89, 126], vs. 85 % [66, 136] p = 0.04,
Fig. 5). Maximal cellular oxygen consumption was avail-
able on 38 patients (19 in the placebo group and 19
in the thiamine group). We found a significant difference
in post-operative relative maximal oxygen consumption
between the thiamine and placebo group (107 % [86, 155],
vs. 90 % [54, 125], p = 0.02, Fig. 5).
Clinical outcomes
There was no difference in time to extubation (8.3 hours
[5.0, 19.2] vs. 7.4 hours [5.5, 12.3], p = 0.51) or time on
vasopressors (12.8 hours [4.0, 21.1] vs. 9.3 hours [2.1,
22.1], p = 0.70) between the thiamine and placebo group.
There was no difference in intensive care unit length of
stay (2.4 days [1.1, 4.2] vs. 2.3 days [1.4, 4.0], p = 0.66) or
in hospital length of stay (5 days [4, 8] vs. 5 days [4, 7],
p = 0.49). There was no difference between the two
groups in post-operative complications (see Table 3). One
patient died in the placebo group and none in the
thiamine group. No side effects of the study medication
were reported in either group.
Subgroups analyses
Twenty-eight patients had a pre-surgery thiamine level
below 14 mmol/L (the median of the entire cohort); 14
in each group. In this subgroup, there was no difference
in the post-operative lactate level between those receiv-
ing thiamine and placebo (1.7 mmol/L [1.5, 2.4] vs.
2.1 mmol/L [1.6, 2.6], p = 0.32). Twenty-one patients had
a EuroSCORE II above 4.0 %; 12 in the placebo group
and nine in the thiamine group. There was no difference
between the groups in post-operative lactate (3.0 mmol/L
[2.1, 4.0] vs. 2.3 mmol/L [1.9, 3.5], p = 0.42) in this
subgroup. Twenty-eight patients had diabetes; 14 in
each group. There was no difference in post-operative







1 5 (17) 6 (18)
2 0 (0) 5 (15)
3 13 (43) 14 (42)
4 11 (37) 8 (24)
5 1 (3) 0 (0)
Valve surgery 0.15
None 17 (55) 22 (67)
Aortic 13 (42) 7 (21)
Mitral 1 (3) 4 (12)
Other procedure 2 (6) 1 (3) 0.61
Intra-operative
complication(s)
2 (6) 0 (0) 0.23
Length of surgery (min) 211 (186, 251) 210 (191, 226) 0.56
Bypass time (min) 95 (69, 118) 80 (72, 96) 0.24
Cross-clamp time (min) 77 (54, 98) 63 (54, 76) 0.13
Received red blood cells 9 (29) 5 (15) 0.23
Fluids/transfusion (mL)
Saline 1000 (500, 1500) 1000 (400, 1800) 0.84
Lactated Ringer’s 1700 (1000, 2000) 1600 (1200, 2100) 0.85
Cell saver 400 (300, 450) 250 (300, 430) 0.49
Estimated blood loss (mL)b 200 (123, 500) 200 (123, 500) 0.79
Urine output (mL) 350 (265, 600) 515 (325, 710) 0.13
aCategorical variables are presented as count (frequency) and continuous
variables as median (quartiles)
bAs estimated by the surgeon. Missing on seven patients
Fig. 3 Lactate levels over time between the two groups. There was no diff
endpoint of lactate levels immediately after the surgery (2.0 [1.5, 2.6] mmol/
median, and 3rd quartile. The whiskers represent the 10th and 90th percentile
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vs. 2.0 mmol/L [1.7, 2.3], p = 0.43).
Discussion
In this phase II trial, we found no difference in post-
operative lactate levels or clinical outcomes between
patients receiving thiamine or placebo. We did find a sig-
nificant difference in post-operative cellular and global
oxygen consumption between the two groups.
To our knowledge, this is the second randomized,
placebo-controlled study to date to examine the efficacy
of thiamine in this patient population. Recently, Luger
et al. enrolled 30 patients undergoing cardiac surgery
[47]. Patients were randomized to one dose of pre-
operative thiamine (300 mg) or placebo. Similar to our
findings, they found no difference in post-operative lac-
tate levels or clinical outcomes. There are a few key dif-
ferences between the study by Luger et al. and that
presented here. First, we enrolled more than twice the
number of patients. Second, we only included moderate-
to high-risk patients (i.e., those with a EuroSCORE II >
1.5 %). Third, we provided two doses of thiamine: one
before and one after the surgery. Lastly, we included a
number of additional outcomes including PDH measure-
ments, global and cellular oxygen consumption, and
more granular clinical outcomes including an assess-
ment of post-operative complications. Despite these dif-
ferences, the findings were largely similar.
Donnino et al. recently found that thiamine did not de-
crease 24-hour lactate levels as compared to placebo in
the overall group of patients (n = 88) with septic shock
and elevated lactate (>3 mmol/L). However, in those witherence between the thiamine and placebo groups in the primary
L vs. 2.0 [1.7, 2.4], p = 0.75). The boxplots represent the 1st quartiles,
and outliers are marked with dots
Fig. 4 PDH values. Relative PDH activity (a), quantity (b) and specific activity (c) post-surgery and 6 hours post-surgery. Values were calculated as
relative to the pre-surgery level, which was set at 100 %. The y-axis is logarithmic to better illustrate the findings. The boxplots represent the 1st
quartiles, median, and 3rd quartile. The whiskers represent the 10th and 90th percentile and outliers are marked with dots
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24-hour lactate levels as compared to placebo and there
was a signal toward decreased mortality in the thiamine
group [48]. In the current study, only one patient was
thiamine deficient at baseline and it is possible that
thiamine administration only has clinical utility in this
subgroup of patients. Alternatively, thiamine could be
beneficial for the group that develops thiamine deficiency
during surgery but there is no way to assess this subgroup
in the current study since provision of thiamine in the
study arm precludes the capacity to determine who would
have become deficient.
We used post-operative lactate levels as the primary
outcome for multiple reasons. First, if thiamine were to
improve PDH activity, as hypothesized, pyruvate should
be converted to acetyl-coenzyme A leading to increased
oxygen utilization and decreased lactate levels. Second,
multiple studies have found an association between
elevated post-operative lactate levels and increasedFig. 5 Cellular oxygen consumption. We found a significant difference in pos
126] vs. 85 % [66, 136], p = 0.04) and a significant difference in cellular maxima
125], p = 0.02). The boxplots represent the 1st quartiles, median, and 3rd
liers are marked with dots. The y-axis is logarithmic to better illustrate the findmorbidity and mortality [5–10]. In a recent study, we
found that post-operative lactate levels were associated
with hospital and intensive care unit length of stay as well
as post-operative non-surgical complications. This associ-
ation remained after adjusting for more than 25 patient
and surgical characteristics indicating that lactate could be
a suitable surrogate for more patient-centered outcomes
[10]. Lastly, as a continuous outcome, lactate levels are a
reasonable outcome in a phase II trial from a statistical
point of view. However, the post-operative lactate levels in
the placebo group were lower than anticipated minimizing
the potential for a treatment effect.
The finding that relative PDH activity was decreased
in the thiamine group was unanticipated, remains largely
unexplained, and could be a chance finding potentially
due to baseline imbalances (i.e., a post hoc analysis ac-
counting for baseline PDH activity showed no signifi-
cant difference between groups). One challenge in
measuring PDH activity includes replicating the in vivot-surgery relative basal oxygen consumption between groups (99 % [89,
l oxygen consumption between groups (107 % [86, 155] vs. 90 % [54,
quartile. The whiskers represent the 10th and 90th percentile and out-
ings






Atrial fibrillation 12 (39) 12 (36) 1.00
Renal failure 1 (3) 2 (6) 1.00
Stroke 0 (0) 0 (0) 1.00
Myocardial infarction 0 (0) 0 (0) 1.00
Acute respiratory distress syndrome 1 (3) 0 (0) 0.48
Infection 5 (16) 5 (15) 1.00
Delirium 3 (10) 4 (12) 1.00
At least one complication 16 (52) 16 (48) 1.00
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described in detail elsewhere [38], measures PDH activ-
ity in vitro in an “ideal” environment which includes
the addition of a small amount of thiamine in order for
the reaction to run. The provision of in vitro thiamine
(even at small levels) limits the between-group com-
parison and might therefore not reflect in vivo PDH
values. Future studies examining the administration of
thiamine or other modulators of PDH might consider
using measures of in vivo PDH activity although these
methods are considerably more complex and might not
be feasible in the CABG population [49].
We found that thiamine significantly improved global
oxygen consumption after CABG surgery. For an average
80 kg patient the increase would be approximately 30 mL/
min. In an open-label trial of thiamine administration in
the critically ill, Berg et al. found that thiamine improved
oxygen consumption [50], consistent with the findings re-
ported here. We also found that cellular oxygen consump-
tion was increased in the group receiving thiamine. We
are not aware of any previous studies examining the effect
of thiamine (or other clinical interventions) on cellular
oxygen consumption. Although the improvements in
cellular and global oxygen consumption did not result
in improved clinical outcomes in the current trial, fu-
ture studies should examine whether improvements in
oxygen consumption could improve patient-centered
outcomes particularly in diseases where ongoing im-
pairment of oxygen consumption is believed to be
pathologic and causative of organ injury. The fact that
we found a difference between groups in oxygen con-
sumption, but no difference in lactate levels may indi-
cate that lactate elevation in this context is not solely
related to oxygen consumption but could reflect other
mechanisms such as decreased clearance or excessive
adrenergic stimulation [12, 51]. However, this remains
speculative and will require additional studies.
The findings from the current study should be inter-
preted in the context of the study limitations. The sample
size was relatively small and we might have beenunderpowered to detect differences between groups espe-
cially in the clinical outcomes. We only provided two doses
of thiamine. While subsequent doses would not have af-
fected our primary endpoint, they could affect more long-
term outcomes. As noted above, the post-operative lactate
levels were lower than expected and it is possible that in-
cluding a more high-risk population with higher propensity
for high post-operative lactate levels could have yielded dif-
ferent results. It is unknown whether measurements of
PDH and oxygen consumption in PBMCs are representa-
tive of more relevant tissue such as the heart or the brain.
Lastly, although the global oxygen consumption measure-
ments used in this study has been validated [40, 41], this
measurement is currently not considered the gold stand-
ard. The oxygen consumption results should be consid-
ered exploratory and hypothesis generating.
Conclusions
In this randomized, placebo-controlled, double-blind,
phase II trial, we found no difference in post-operative
lactate levels or clinical outcomes between patients re-
ceiving thiamine or placebo. We found a significant in-
crease in post-operative oxygen consumption in patients
receiving thiamine.
Key messages
 A randomized, double-blind, placebo-controlled trial
of thiamine in 64 patients undergoing coronary
artery bypass grafting was performed
 There was no difference in post-operative lactate
levels between the two groups
 There was no difference in clinical outcomes
between groups
 Patients in the thiamine groups had significantly higher
post-operative cellular and global oxygen consumption
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